Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZX008 (fenfluramine) in CDKL5 deficiency disorder (CDD) – randomized, double-blind, placebo-controlled Phase 3 with open-label extension
2021-003222-76Phase 3Active
- Sponsor
- Zogenix, Inc.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in CDKL5 deficiency disorder (CDD) comparing ZX008 (fenfluramine hydrochloride) with Placebo (2 arms). Primary endpoint: Primary endpoint (Part 1 and overall study). Started Mar 2022; status: active.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on 2021-003222-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003222-76.